{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T09:10:09Z","timestamp":1759569009111,"version":"build-2065373602"},"reference-count":46,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2013,3,1]],"date-time":"2013-03-01T00:00:00Z","timestamp":1362096000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,3,1]],"date-time":"2013-03-01T00:00:00Z","timestamp":1362096000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,8]],"date-time":"2022-06-08T00:00:00Z","timestamp":1654646400000},"content-version":"vor","delay-in-days":3386,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","exphem.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental Hematology"],"published-print":{"date-parts":[[2013,3]]},"DOI":"10.1016\/j.exphem.2012.10.018","type":"journal-article","created":{"date-parts":[[2012,11,8]],"date-time":"2012-11-08T04:05:50Z","timestamp":1352347550000},"page":"231-240","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Thalidomide maintenance therapy maturates the T cell compartment and compromises antigen-specific antitumor immunity in patients with multiple myeloma"],"prefix":"10.1016","volume":"41","author":[{"given":"Isabelle","family":"Herth","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mathias","family":"Witzens-Harig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philipp","family":"Beckhove","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dirk","family":"Hose","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tobias","family":"Meissner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brigitte","family":"Neuber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melanie","family":"Engelhardt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00fcrgen","family":"Haas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kai","family":"Neben","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony D.","family":"Ho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernard","family":"Klein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hartmut","family":"Goldschmidt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Hundemer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.exphem.2012.10.018_bib1","doi-asserted-by":"crossref","first-page":"5720","DOI":"10.1200\/JCO.2008.21.1060","article-title":"Achievement of at least very good partial response is a simple and robust prognostic factor in patients with multiple myeloma treated with high-dose therapy: Long-term analysis of the IFM 99-02 and 99-04 Trials","volume":"27","author":"Harousseau","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.exphem.2012.10.018_bib2","doi-asserted-by":"crossref","first-page":"3510","DOI":"10.1200\/JCO.2008.19.9240","article-title":"Phase II study of thalidomide plus dexamethasone induction followed by tandem melphalan-based autotransplantation and thalidomide-plus-prednisone maintenance for untreated multiple myeloma: A southwest oncology group trial (S0204)","volume":"27","author":"Hussein","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.exphem.2012.10.018_bib3","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1200\/JCO.1999.17.1.208","article-title":"Molecular and clinical remissions in multiple myeloma: role of autologous and allogeneic transplantation of hematopoietic cells","volume":"17","author":"Corradini","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.exphem.2012.10.018_bib4","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1038\/sj.bmt.1702826","volume":"27","author":"Bjorkstrand","year":"2001","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.exphem.2012.10.018_bib5","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1007\/s00277-003-0685-2","article-title":"Joint HOVON-50\/GMMG-HD3 randomized trial on the effect of thalidomide as part of a high-dose therapy regimen and as maintenance treatment for newly diagnosed myeloma patients","volume":"82","author":"Goldschmidt","year":"2003","journal-title":"Ann Hematol"},{"key":"10.1016\/j.exphem.2012.10.018_bib6","doi-asserted-by":"crossref","first-page":"3289","DOI":"10.1182\/blood-2006-05-022962","article-title":"Maintenance therapy with thalidomide improves survival in patients with multiple myeloma","volume":"108","author":"Attal","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2012.10.018_bib7","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1200\/JCO.2009.25.6081","article-title":"Long-term follow-up of autotransplantation trials for multiple myeloma: update of protocols conducted by the intergroupe francophone du myelome, southwest oncology group, and university of arkansas for medical sciences","volume":"28","author":"Barlogie","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.exphem.2012.10.018_bib8","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1182\/blood-2011-06-357038","article-title":"The role of maintenance thalidomide therapy in multiple myeloma: MRC myeloma IX results and meta-analysis","volume":"119","author":"Morgan","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2012.10.018_bib9","doi-asserted-by":"crossref","first-page":"3115","DOI":"10.1182\/blood-2008-03-145235","article-title":"Thalidomide arm of Total Therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities","volume":"112","author":"Barlogie","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2012.10.018_bib10","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1056\/NEJMoa1114083","article-title":"Lenalidomide after stem-cell transplantation for multiple myeloma","volume":"366","author":"McCarthy","year":"2012","journal-title":"New Engl J Med"},{"key":"10.1016\/j.exphem.2012.10.018_bib11","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1056\/NEJMoa1114138","article-title":"Lenalidomide maintenance after stem-cell transplantation for multiple myeloma","volume":"366","author":"Attal","year":"2012","journal-title":"New Engl J Med"},{"key":"10.1016\/j.exphem.2012.10.018_bib12","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1182\/blood-2005-10-4184","article-title":"Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: Therapeutic implications","volume":"108","author":"Chang","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2012.10.018_bib13","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1007\/s00262-008-0620-4","article-title":"The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells","volume":"58","author":"Galustian","year":"2009","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.exphem.2012.10.018_bib14","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1182\/blood.V98.1.210","article-title":"Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma","volume":"98","author":"Davies","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2012.10.018_bib15","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1084\/jem.187.11.1885","article-title":"Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset","volume":"187","author":"Haslett","year":"1998","journal-title":"J Exp Med"},{"key":"10.1016\/j.exphem.2012.10.018_bib16","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1126\/science.272.5270.1947","article-title":"Induction of bystander T cell proliferation by viruses and type I interferon in\u00a0vivo","volume":"272","author":"Tough","year":"1996","journal-title":"Science"},{"key":"10.1016\/j.exphem.2012.10.018_bib17","doi-asserted-by":"crossref","first-page":"5363","DOI":"10.4049\/jimmunol.172.9.5363","article-title":"Role of cross-talk between IFN-alpha-induced monocyte-derived dendritic cells and NK cells in priming CD8+ T cell responses against human tumor antigens","volume":"172","author":"Tosi","year":"2004","journal-title":"J Immunol"},{"key":"10.1016\/j.exphem.2012.10.018_bib18","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.4049\/jimmunol.1002460","article-title":"Lenalidomide enhances antigen-specific activity and decreases CD45RA expression of T cells from patients with multiple myeloma","volume":"187","author":"Neuber","year":"2011","journal-title":"J Immunol"},{"key":"10.1016\/j.exphem.2012.10.018_bib19","doi-asserted-by":"crossref","first-page":"2828","DOI":"10.1182\/blood.V96.8.2828","article-title":"Tumor-specific recognition of human myeloma cells by idiotype-induced CD8(+) T cells","volume":"96","author":"Li","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2012.10.018_bib20","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1182\/blood.V97.6.1750","article-title":"Idiotype-specific cytotoxic T lymphocytes in multiple myeloma: evidence for their capacity to lyse autologous primary tumor cells","volume":"97","author":"Wen","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2012.10.018_bib21","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1097\/CJI.0b013e3181a95198","article-title":"Melan-A\/MART1 analog peptide triggers anti-myeloma T-cells through crossreactivity with HM1.24","volume":"32","author":"Christensen","year":"2009","journal-title":"J Immunother"},{"key":"10.1016\/j.exphem.2012.10.018_bib22","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.exphem.2006.01.008","article-title":"Identification of a new HLA-A2-restricted T-cell epitope within HM1.24 as immunotherapy target for multiple myeloma","volume":"34","author":"Hundemer","year":"2006","journal-title":"Exp Hematol"},{"key":"10.1016\/j.exphem.2012.10.018_bib23","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1080\/028418600750063523","article-title":"Idiotype immunity (natural and vaccine-induced) in early stage multiple myeloma","volume":"39","author":"Osterborg","year":"2000","journal-title":"Acta Oncol"},{"key":"10.1016\/j.exphem.2012.10.018_bib24","doi-asserted-by":"crossref","first-page":"2671","DOI":"10.1002\/eji.1830261119","article-title":"Peripheral T cell tolerance as a tumor escape mechanism: deletion of CD4+ T cells specific for a monoclonal immunoglobulin idiotype secreted by a plasmacytoma","volume":"26","author":"Bogen","year":"1996","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.exphem.2012.10.018_bib25","doi-asserted-by":"crossref","first-page":"4071","DOI":"10.1182\/blood-2006-04-016980","article-title":"Optimizing immunotherapy in multiple myeloma: Restoring the function of patients' monocyte-derived dendritic cells by inhibiting p38 or activating MEK\/ERK MAPK and neutralizing interleukin-6 in progenitor cells","volume":"108","author":"Wang","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2012.10.018_bib26","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1182\/blood.V77.8.1776.1776","article-title":"Predominant T cell receptor V gene usage in patients with abnormal clones of B cells","volume":"77","author":"Janson","year":"1991","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2012.10.018_bib27","doi-asserted-by":"crossref","first-page":"127","DOI":"10.3109\/10428199909093733","article-title":"Altered T cell repertoire usage in CD4 and CD8 subsets of multiple myeloma patients: A Study of the Eastern Cooperative Oncology Group (E9487)","volume":"33","author":"Kay","year":"1999","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.exphem.2012.10.018_bib28","doi-asserted-by":"crossref","first-page":"3297","DOI":"10.1182\/blood.V87.8.3297.bloodjournal8783297","article-title":"Clonal populations of CD4+ and CD8+ T cells in patients with multiple myeloma and paraproteinemia","volume":"87","author":"Moss","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2012.10.018_bib29","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1084\/jem.171.3.659","article-title":"Presence of clonal T cell populations in chronic B lymphocytic leukemia and smoldering myeloma","volume":"171","author":"Wen","year":"1990","journal-title":"J Exp Med"},{"key":"10.1016\/j.exphem.2012.10.018_bib30","doi-asserted-by":"crossref","first-page":"4281","DOI":"10.4049\/jimmunol.153.9.4281","article-title":"T cell repertoire in patients with B chronic lymphocytic leukemia. Evidence for multiple in\u00a0vivo T cell clonal expansions","volume":"153","author":"Farace","year":"1994","journal-title":"J Immunol"},{"key":"10.1016\/j.exphem.2012.10.018_bib31","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1046\/j.1365-2141.1997.d01-2021.x","article-title":"Idiotype-specific T lymphocytes in monoclonal gammopathies: Evidence for the presence of CD4+ and CD8+ subsets","volume":"96","author":"Yi","year":"1997","journal-title":"Br J Haematol"},{"key":"10.1016\/j.exphem.2012.10.018_bib32","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.1182\/blood-2004-01-0366","article-title":"Enrichment of functional CD8 memory T cells specific for MUC1 in bone marrow of patients with multiple myeloma","volume":"105","author":"Choi","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2012.10.018_bib33","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1038\/sj.leu.2400714","article-title":"The prognostic significance of T cell receptor beta gene rearrangements and idiotype-reactive T cells in multiple myeloma","volume":"11","author":"Brown","year":"1997","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2012.10.018_bib34","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1046\/j.1365-2141.2000.02131.x","article-title":"T-cell expansions in patients with multiple myeloma have a phenotype of cytotoxic T cells","volume":"110","author":"Raitakari","year":"2000","journal-title":"Br J Haematol"},{"key":"10.1016\/j.exphem.2012.10.018_bib35","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1182\/blood.V98.9.2817","article-title":"Clonal cytotoxic T cells are expanded in myeloma and reside in the CD8(+)CD57(+)CD28(\u2212) compartment","volume":"98","author":"Sze","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2012.10.018_bib36","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1038\/sj.bjc.6602407","article-title":"Characteristics of CD4+CD25+ regulatory T cells in the peripheral circulation of patients with head and neck cancer","volume":"92","author":"Schaefer","year":"2005","journal-title":"Br J Cancer"},{"key":"10.1016\/j.exphem.2012.10.018_bib37","first-page":"606","article-title":"Increase of regulatory T cells in the peripheral blood of cancer patients","volume":"9","author":"Wolf","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.exphem.2012.10.018_bib38","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1158\/1078-0432.CCR-06-1603","article-title":"Long-term idiotype vaccination combined with interleukin-12 (IL-12), or IL-12 and granulocyte macrophage colony-stimulating factor, in early-stage multiple myeloma patients","volume":"13","author":"Hansson","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.exphem.2012.10.018_bib39","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.3109\/10428190903216804","article-title":"Prognostically significant cytotoxic T cell clones are stimulated after thalidomide therapy in patients with multiple myeloma","volume":"50","author":"Brown","year":"2009","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.exphem.2012.10.018_bib40","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.3324\/haematol.11208","article-title":"Patients with multiple myeloma treated with thalidomide: evaluation of clinical parameters, cytokines, angiogenic markers, mast cells and marrow CD57+ cytotoxic T cells as predictors of outcome","volume":"92","author":"Mileshkin","year":"2007","journal-title":"Haematologica"},{"key":"10.1016\/j.exphem.2012.10.018_bib41","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1038\/leu.2009.98","article-title":"Thalidomide exerts distinct molecular antileukemic effects and combined thalidomide\/fludarabine therapy is clinically effective in high-risk chronic lymphocytic leukemia","volume":"23","author":"Giannopoulos","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2012.10.018_bib42","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1038\/leu.2008.247","article-title":"Lenalidomide alone or in combination with dexamethasone is highly effective in patients with relapsed multiple myeloma following allogeneic stem cell transplantation and increases the frequency of CD4+Foxp3+ T cells","volume":"23","author":"Minnema","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2012.10.018_bib43","first-page":"538","article-title":"[Effects of thalidomide on CD4(+)CD25(+) T regulatory cells in patients with multiple myeloma]","volume":"16","author":"Yang","year":"2008","journal-title":"Zhongguo shi yan xue ye xue za zhi"},{"key":"10.1016\/j.exphem.2012.10.018_bib44","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1111\/j.1365-2141.2009.08014.x","article-title":"Lenalidomide treatment of chronic lymphocytic leukaemia patients reduces regulatory T cells and induces Th17 T helper cells","volume":"148","author":"Idler","year":"2010","journal-title":"Br J Haematol"},{"key":"10.1016\/j.exphem.2012.10.018_bib45","doi-asserted-by":"crossref","first-page":"2862","DOI":"10.1128\/JVI.02528-08","article-title":"Distinct profiles of cytotoxic granules in memory CD8 T cells correlate with function, differentiation stage, and antigen exposure","volume":"83","author":"Harari","year":"2009","journal-title":"J Virol"},{"key":"10.1016\/j.exphem.2012.10.018_bib46","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/s10067-007-0786-8","article-title":"Thalidomide has both anti-inflammatory and regulatory effects in Behcet\u2019s disease","volume":"27","author":"Direskeneli","year":"2008","journal-title":"Clin Rheumatol"}],"container-title":["Experimental Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301472X12005358?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301472X12005358?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T08:30:02Z","timestamp":1759566602000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0301472X12005358"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,3]]},"references-count":46,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013,3]]}},"alternative-id":["S0301472X12005358"],"URL":"https:\/\/doi.org\/10.1016\/j.exphem.2012.10.018","relation":{},"ISSN":["0301-472X"],"issn-type":[{"type":"print","value":"0301-472X"}],"subject":[],"published":{"date-parts":[[2013,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Thalidomide maintenance therapy maturates the T cell compartment and compromises antigen-specific antitumor immunity in patients with multiple myeloma","name":"articletitle","label":"Article Title"},{"value":"Experimental Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.exphem.2012.10.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 ISEH - Society for Hematology and Stem Cells. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}